Syndax Pharmaceuticals (SNDX) Invested Capital: 2015-2025
Historic Invested Capital for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Sep 2025 value amounting to $115.4 million.
- Syndax Pharmaceuticals' Invested Capital fell 68.50% to $115.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.4 million, marking a year-over-year decrease of 68.50%. This contributed to the annual value of $300.2 million for FY2024, which is 45.82% down from last year.
- Per Syndax Pharmaceuticals' latest filing, its Invested Capital stood at $115.4 million for Q3 2025, which was down 26.68% from $157.4 million recorded in Q2 2025.
- Syndax Pharmaceuticals' Invested Capital's 5-year high stood at $554.2 million during Q4 2023, with a 5-year trough of $115.4 million in Q3 2025.
- For the 3-year period, Syndax Pharmaceuticals' Invested Capital averaged around $348.2 million, with its median value being $366.4 million (2024).
- Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 216.75% in 2021, then slumped by 68.50% in 2025.
- Over the past 5 years, Syndax Pharmaceuticals' Invested Capital (Quarterly) stood at $408.6 million in 2021, then grew by 14.42% to $467.4 million in 2022, then grew by 18.56% to $554.2 million in 2023, then tumbled by 45.82% to $300.2 million in 2024, then tumbled by 68.50% to $115.4 million in 2025.
- Its Invested Capital stands at $115.4 million for Q3 2025, versus $157.4 million for Q2 2025 and $215.1 million for Q1 2025.